MannKind (MNKD) Reports Q1 Loss of $0.25/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
MannKind Corporation Reports 2018 First Quarter Financial Results
May 9, 2018 4:01 PM EDTQ1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 (+234% under the 2017 revenue recognition model)Q1 2018 Net Cash Used in Operating Activities was $21.7 millionSTAT study results accepted for presentation at American Diabetes Associations 78th scientific sessionsInitiated Phase 1 clinical trial of Treprostinil Technosphere             Â
WESTLAKE VILLAGE, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today reported financial results for the first quarter ended March 31, 2018.
We started 2018 with solid growth of 184% in quarterly Afrezza sales year-over-year, which reflects our progression as a... More
